文献速递神经肿瘤

特应性病史与IDH突变型及野生型低级别胶质瘤预后改善相关

History of atopy confers improved outcomes in IDH mutant and wildtype lower grade gliomas.
PubMed 文献 · J Neurooncol · 2021-10-29

本研究基于TCGA低级别胶质瘤数据,分析特应性病史(哮喘、湿疹、花粉症、动物或食物过敏)与患者生存的关系。374例患者中,有特应性病史者总生存期更长(145.3 vs. 81.5个月,p=0.0195),IDH突变患者中特应性病史亦与更长总生存期相关(158.8 vs. 85个月,p=0.035)。多因素分析显示特应性对生存的影响独立于IDH状态和病理分级,BDNF通路上游激活可能解释该差异。

要点

  • 特应性病史与低级别胶质瘤患者更长总生存期相关。
  • IDH突变患者中特应性病史仍与生存获益相关。
  • 特应性对生存的影响独立于IDH状态和病理分级。

核心结论

  • 特应性病史为弥漫性低级别胶质瘤患者带来生存获益。
  • BDNF通路激活可能是观察到的生存差异的驱动因素。

研究设计与样本

  • 研究下载TCGA低级别胶质瘤数据,并获取IDH、TERT、1p/19q及ATRX突变状态和遗传改变信息。
  • 根据TCGA记录的哮喘、湿疹、花粉症、动物或食物过敏史判定特应性状态,缺失变量患者被排除。
  • 最终纳入374例低级别胶质瘤患者进行分析。

主要发现

  • 有特应性病史患者总生存期长于无特应性病史者(145.3 vs. 81.5个月,p=0.0195)。
  • IDH突变患者中,有特应性病史者总生存期长于无特应性病史者(158.8 vs. 85个月,p=0.035)。
  • 多因素Cox回归显示特应性对生存的影响独立于IDH(p=0.002,HR 0.257,95%CI 0.109-0.604)和病理分级(p<0.001,HR 0.217,95%CI 0.107-0.444)。
  • 另一多因素分析项显示p=0.004,HR 2.72,95%CI 1.373-5.397。
  • 有特应性病史患者与无特应性病史者在治疗反应上无差异。

临床怎么用

  • 特应性病史或可作为低级别胶质瘤患者生存预后的参考信息。
  • IDH突变状态与特应性病史可共同用于预后分层评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A history of atopy or allergy has been shown to be protective against the development of glioma, however the effect of atopy on patient outcomes, especially in conjunction with the survival benefit associated with IDH mutation, has not yet been investigated, and is the focus of the study we present here. METHODS: Low grade glioma (LGG) data from the TCGA was downloaded, along with IDH, TERT, 1p/19q and ATRX mutational status and genetic alterations. History of asthma, eczema, hay fever, animal, or food allergies, as documented in TCGA, was used to determine patient atopy status. Patients with missing variables were excluded from the study. RESULTS: 374 LGG studies were included. Patients with a history of atopy demonstrated longer overall survival (OS) compared to those without (145.3 vs. 81.5 months, p = 00.0195). IDH mutant patients with atopy had longer OS compared those without atopy (158.8 vs. 85 months, p = 0.035). Multivariate cox regression analysis demonstrated that the effects of atopy on survival were independent of IDH and histological grade, (p = 0.002, HR 0.257, 95% 0.109-0.604), (p = < 0.001, HR 0.217, 95% 0.107-0.444), and (p = 0.004, HR 2.72, 95% 1.373-5.397), respectively. In terms of treatment outcomes, patients with atopy did not differ in treatment response compared to their counterpart. Pathway analysis demonstrated an upstream activation of the BDNF pathway (p = 0.00027). CONCLUSION: A history of atopy confers a survival benefit in patients with diffuse low-grade glioma. Activation of the BDNF pathway may drive the observed differences.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Jaman E, Zhang X, Sandlesh P, et al. History of atopy confers improved outcomes in IDH mutant and wildtype lower grade gliomas. J Neurooncol. 2021. PMID: 34714520. doi:10.1007/s11060-021-03854-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。